Mirum Pharmaceuticals (MIRM) Short-term Investments (2019 - 2026)

Mirum Pharmaceuticals' Short-term Investments history runs 8 years deep, the most recent figure standing at $61.4 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 6.83% year-over-year to $61.4 million in Q1 2026; TTM through Mar 2026 was $61.4 million, a 6.83% decrease from a year earlier, with the FY2025 full-year figure at $86.6 million, up 49.87% from the prior year.
• Short-term Investments slipped to $61.4 million in Q1 2026 per MIRM's latest filing, from $86.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $149.6 million in Q3 2022 and bottomed at $3.0 million in Q3 2023.
• The 5-year median for Short-term Investments is $69.7 million (2022), against an average of $73.5 million.
• Across the five-year window, Short-term Investments slumped 98.01% in 2023 and soared 1969.2% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $123.7 million in 2022, then plunged by 97.6% to $3.0 million in 2023, then surged by 1845.88% to $57.8 million in 2024, then jumped by 49.87% to $86.6 million in 2025, then declined by 29.19% to $61.4 million in 2026.
• Per Business Quant, the three latest MIRM Short-term Investments figures stand at $61.4 million (Q1 2026), $86.6 million (Q4 2025), and $93.5 million (Q3 2025).